Molybdenum Breakthrough on a Monday Morning Eluate
Monday, 07:15. Your 99mTc/99Mo generator, last eluted Sunday at 06:00 (25 hours earlier), yields 1,100 mCi (40.7 GBq) in 5.0 mL. The shielded assay of Mo-99 in that eluate reads 220 µCi (8.1 MBq); the unshielded 99mTc assay reads 1,100 mCi. At 06:50 you used 300 mCi of this eluate to prepare 99mTc-MDP unit doses for three bone-scan patients now sitting in the waiting room (09:00, 09:30, 10:00). An 8-year-old is booked at 11:00 for a Meckel diverticulum study with pertechnetate. The generator's three previous eluates ran 0.02–0.04 µCi Mo-99 per mCi 99mTc. Your SOP quotes the limit at the time of administration: 0.15 µCi Mo-99 per mCi 99mTc (0.15 kBq/MBq). The RSO is unavailable until 13:00.
1. Perform the acceptance calculation and state your decision about this eluate. What would you verify before condemning the generator?
Read the worked answer
Calculation: 220 µCi ÷ 1,100 mCi = 0.20 µCi Mo-99 per mCi 99mTc, which is 1.3× the 0.15 limit.
Decision: reject the eluate. It may not be used for any preparation - MDP, pertechnetate, or otherwise. The limit applies at the time of administration, and the ratio does not improve with time (see next task).
Before blaming the generator, verify the assay itself, because a false positive wastes a generator and a day's schedule:
- Mo-99 measured in the dose calibrator with the correct shield/setting for that geometry, and corrected for the Tc-99m contribution in the same geometry.
- Eluate volume recorded and the generator's elution history checked (25-hour ingrowth after a weekend is exactly when breakthrough rises in a wet column).
- No visible column voiding, no unusual elution pressure, no evidence the saline vial was breached.
If the assay is technically sound and the value is genuinely 0.20, the eluate is rejected and the generator is re-eluted and re-tested before any further use.
2. A colleague suggests simply storing the eluate and re-testing at 15:00. Evaluate that plan quantitatively.
Read the worked answer
The plan fails, and it fails predictably.
Mo-99 (t½ ≈ 66 h) decays far more slowly than 99mTc (t½ ≈ 6.0 h), so the ratio rises with time.
At 15:00, 8 hours from now:
- 99mTc: 1,100 × 0.5^(8/6) ≈ 437 mCi
- Mo-99: 220 × 0.5^(8/66) ≈ 202 µCi
- Ratio: 202 ÷ 437 ≈ 0.46 µCi/mCi - roughly triple the current value and three times the limit.
Correct actions instead:
- Re-elute (frequent elution is the standard remedy for rising breakthrough in a wet generator) and re-assay the fresh eluate.
- If the fresh eluate is still above 0.15, remove the generator from service, document, notify the RSO, and obtain unit doses or a replacement generator from another source.
- Do not "dilute" or "average" the result against previous good eluates - each eluate stands on its own assay.
3. What happens to the three waiting bone-scan patients and the 11:00 pediatric study? What documentation is required?
Read the worked answer
The three MDP doses must not be injected. They were compounded from a rejected eluate.
- Segregate and label the syringes "NOT FOR HUMAN USE," hold them for decay (≈10 half-lives, about 60 hours), and log the disposition.
- Notify the nuclear medicine physician and the RSO, and note the finding in the generator/QC log with the assay data, the calculation and the corrective action.
- Rebook or source product: re-elute and re-assay; if compliant, prepare fresh doses and run the patients later the same morning. If not, obtain unit doses from another generator or reschedule.
Pediatric pertechnetate at 11:00: proceed only with a verified compliant eluate. An 8-year-old should not receive a dose compounded from rejected material, and pertechnetate is not exempt just because the study is simple.
If any dose had already been administered: notify the AU and RSO, calculate the Mo-99 activity delivered (0.20 µCi per mCi of dose), document, and follow institutional policy. Mo-99 is bone-seeking with a long half-life and high-energy emissions, so the event is taken seriously even though the activities involved are small; the RSO determines reporting obligations, since exceeding a breakthrough limit is not itself a 10 CFR 35.3045 medical event.